4D Molecular Therapeutics, Inc. (FDMT) insider sells 26,842 shares under plan

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. director and officer David Kirn sold 26,842 shares of common stock on August 4, 2026 at a weighted average price of $10.2301 per share. The sale was executed in multiple trades between $10.07 and $10.42 pursuant to a 10b5-1 trading plan adopted January 9, 2026. After this transaction, he directly owns 844,895 common shares.

Insider Trade Summary 10b5-1

Net Seller: 26,842 shares

Net Sell 1 txn

Insider Kirn David

Role See Remarks

Sold 26,842 shs ($275K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	26,842	$10.2301	$275K

Holdings After Transaction: Common Stock — 844,895 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.
2. F2. The transaction was executed in multiple trades in prices ranging from $10.07 to $10.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Key Figures

Shares sold: 26,842 shares Weighted average sale price: $10.2301 per share Sale price range: $10.07–$10.42 per share +1 more

4 metrics

Shares sold 26,842 shares Common Stock sold by David Kirn on August 4, 2026

Weighted average sale price $10.2301 per share Weighted average price for the 26,842 shares sold

Sale price range $10.07–$10.42 per share Range of prices for multiple trades in the reported sale

Shares owned after transaction 844,895 shares Direct Common Stock holdings of David Kirn after the sale

Key Terms

10b5-1 trading plan, weighted average sale price, open market or private transaction

3 terms

10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan adopted..."

A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.

weighted average sale price financial

"The price reported in Column 4 above reflects the weighted average sale price."

open market or private transaction market

"Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 04:11 PM Accepted by SEC EDGAR 08/05/2026 - 04:10 PM Learn about SEC filing dates

FAQ

What insider transaction did 4D Molecular Therapeutics (FDMT) report in this Form 4?

4D Molecular Therapeutics reported that director and officer David Kirn sold 26,842 shares of common stock on August 4, 2026 at a weighted average price of $10.2301 per share, leaving him with 844,895 directly held shares after the transaction.

At what prices were David Kirn’s FDMT shares sold in this transaction?

David Kirn’s sale of 26,842 FDMT shares was executed in multiple trades at prices ranging from $10.07 to $10.42 per share. The Form 4 reports a weighted average sale price of $10.2301 for these transactions.

How many FDMT shares does David Kirn own after the reported sale?

Following the reported sale, David Kirn directly owns 844,895 shares of 4D Molecular Therapeutics common stock. This figure reflects his holdings immediately after disposing of 26,842 shares in open market or private transactions on August 4, 2026.

Was the FDMT insider sale by David Kirn made under a 10b5-1 trading plan?

Yes. The Form 4 states the transaction was made pursuant to a 10b5-1 trading plan adopted by David Kirn on January 9, 2026. Such plans pre-schedule trades, which can reduce the informational value of the timing of the reported sale.

Is David Kirn’s FDMT stock position reported as direct or indirect ownership?

The Form 4 reports David Kirn’s post-transaction holding of 844,895 FDMT shares as direct ownership. The ownership code is listed as "D," and no nature-of-ownership footnote indicates any trust, fund, or other indirect holding structure for this position.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kirn David

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/04/2026		S(1)		26,842	D	$10.2301(2)	844,895	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

2. The transaction was executed in multiple trades in prices ranging from $10.07 to $10.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

	/s/ Scott Bizily as Attorney-in-Fact for David Kirn	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)